Advertising
FTC Influencer Disclosure Basics for CPG Brands
When a creator recommends a cream, a supplement, or a snack, viewers often assume the person bought it and liked it. If the brand paid them, gave them free product, or promised a commission, that relationship can change how the recommendation should be read. The Federal Trade Commission expects that relationship to be disclosed clearly and conspicuously when it would matter to the audience.
The practical reference for marketers is The FTC’s Endorsement Guides: What People Are Asking, which explains the agency’s Guides Concerning the Use of Endorsements and Testimonials in Advertising in question-and-answer form. The disclosure rules sit next to the ordinary rule that the claims themselves need support. A correct “#ad” does not substantiate “clinically proven.”
What counts as a material connection
A material connection is a relationship that might affect the weight a viewer gives the endorsement. Payment is the obvious case. So is a free product if the brand gave it because it wanted a post. Affiliate links, discount codes that pay the creator, employment, and a family or business tie can also be material. A creator who truly bought the product in a store, with no ask from the brand and no benefit for posting, is in a different position. The brand should not guess. The contract and the seeding list are the record.
Here is a hypothetical, not a real campaign. A skincare brand sends a creator a kit and a note that says “no need to post, but we’d love to see it if you do.” The creator posts a week later with no mention of the gift. The audience still has no way to know the product arrived from the brand. The FTC’s examples treat unexpected free product, given with an expectation of promotion, as something viewers should hear about. “No need to post” in a private email does not disclose the connection on the public video.
Employees who praise the brand’s product in a post or a review have a connection too. A founder filming a routine is advertising. Viewers should be able to tell. The same is true of an agency staffer posting from a personal account.
Clear and conspicuous, on the same surface
The disclosure has to be difficult to miss and easy to understand. “Thanks to the brand” is vague. “Ad,” “Sponsored,” or “Paid partnership with [brand]” is plainer. The FTC has said that burying a disclosure in a long caption, below a “more” fold, or only on a profile page is a weak way to tell people about a connection that appears in the video itself.
Platform tools that label a post as a paid partnership can help, but the brand should look at the actual placement. If the label is easy to overlook, or if the video can be watched without it, the team should not assume the tool finished the job. A spoken disclosure in a video, early enough that people who leave still heard it, is often clearer than a hashtag at the end of a caption. Superimposed text should be readable on a phone, for long enough to read, and not covered by other captions.
Stories, livestreams, and short clips need the disclosure inside the content people actually see. A disclosure in the first frame that disappears, or only in a bio link, does not travel with a reshared clip. If the brand repurposes the creator’s video as its own ad, the paid nature should still be apparent in that ad.
The claim and the disclosure are separate
A disclosure does not make the product claim appropriate. A brief that asks a creator to present a therapeutic outcome creates that implication in the brand’s advertising, whether or not the post is labeled as an ad. FDA’s framework for when presentation makes a product a drug, a cosmetic, or both is summarized in Is It a Cosmetic, a Drug, or Both? The positioning question is discussed in cosmetic vs. drug claims and when cosmetic marketing changes how a product is interpreted.
Proof language has the same split. If the brief asks the creator to present the product as clinically established, the brand needs evidence that fits that impression, not only a disclosure. See what “clinically proven” means. Health-related advertising claims are covered in the FTC’s Health Products Compliance Guidance.
Typical results matter too. If a creator shows an unusual outcome, the FTC expects advertising to be clear about what people can generally expect. A disclosure of payment does not fix a misleading before-and-after.
What the brand still owns
Brands sometimes say the creator “went off script.” The endorsement guides still look at whether the advertiser told endorsers what they can say and paid attention to what they did say. A one-line policy in a contract is weaker than a brief that sets the product story and the disclosure expectation. If a live post is wrong, the useful response is a correction or a takedown, with a record.
Affiliate programs need the same attention to paid-relationship transparency. A tracking code does not tell the audience that the creator earns something when people use it. Sending people to a bio link is not, by itself, a disclosure of a commission.
If a model writes the caption, both the claim and the disclosure can drift. Drafting tools often omit a disclosure because the prompt asked for a natural caption. That problem is part of AI-generated product descriptions.
What deserves attention
- Paid-relationship transparency: payment, free product, commissions, and other benefits that could affect how the endorsement is read.
- Disclosure adequacy: whether the connection is plain inside the content people actually see or hear.
- Product-claim consistency: whether the creator’s story matches the positioning and evidence the brand can stand behind.
- Platform context: whether a built-in label is actually noticeable in that format, including on a phone.
- Repurposed-content risk: ads, stitches, and reused clips that drop the disclosure or change the claim.